US Patent Issued to Arrowhead Pharmaceuticals on July 22 for "RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use" (Wisconsin Inventors)

ALEXANDRIA, Va., July 23 -- United States Patent no. 12,365,897, issued on July 22, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use" was invented by Erik W. Bush (Verona, Wis.), Anthony Nicholas (Oregon, Wis.) and Casi M. Schienebeck (Deerfield, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Mucin 5AC (MUC5AC) gene. The MUC5AC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MUC5AC gene. Pharmaceutical compositions that include one or more MUC5AC RNAi a...